Boundless Bio Quote - BOLD

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

4.43

Bid

4.43

Ask

7.08

Volume

0.00 Day's Range 0.00

4.42 52 Week Range 15.20

Market Cap

98.588M

Previous Close

4.43

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

137,450

Shares Outstanding

22,254,537

Dividend Yield

PE Ratio

-1.99

Earnings Per Share (EPS)

-2.22

Revenue

Net Profit

-49.43M

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical t... Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.boundlessbio.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Boundless Bio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker BOLD. The last closing price for Boundless Bio was US$4.43. Over the last year, Boundless Bio shares have traded in a share price range of US$ 4.42 to US$ 15.20.

Boundless Bio currently has 22,254,537 shares outstanding. The market capitalization of Boundless Bio is US$98.59 million. Boundless Bio has a price to earnings ratio (PE ratio) of -1.99.

Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights

BBI-355 Phase 1/2 POTENTIATE clinical trial ongoing; initiated targeted therapy combinations in patients with tumors with EGFR or FGFR oncogene amplifications First patient dosed in Phase 1/2...

Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable...

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications

STARMAP (Study Treating Acquired Resistance: MAPK Amplifications) is a first-in-human, 3-part, Phase 1/2 study of BBI-825 as a single agent and in combination with select targeted cancer...

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

Findings support the ongoing development of BBI-355, a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1) in Phase 1/2 development, as a differentiated treatment approach for...

Period †	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-1.49	-25.1689189189	5.92	6.24	4.42	240811	4.94062212	CS
4	-4.93	-52.6709401709	9.36	10.13	4.42	122539	6.25467718	CS
12	-9.47	-68.1294964029	13.9	14.18	4.42	137450	9.78165498	CS
26	-9.82	-68.9122807018	14.25	15.2	4.42	155069	10.43125888	CS
52	-9.82	-68.9122807018	14.25	15.2	4.42	155069	10.43125888	CS
156	-9.82	-68.9122807018	14.25	15.2	4.42	155069	10.43125888	CS
260	-33.05	-88.1803628602	37.48	60	4.42	603985	45.79106038	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AXISAxis Auto Finance Inc	$ 0.045 (28.57%)	1,000
NCFNorthcliff Resources Ltd	$ 0.025 (25.00%)	10k
AMMAlmaden Minerals Ltd New	$ 0.105 (23.53%)	154.73k
GFPGreenFirst Forest Products Inc	$ 0.40 (21.21%)	382.15k
AVCNAvicanna Inc	$ 0.35 (18.64%)	437.61k
VGCXVictoria Gold Corp	$ 1.36 (-81.70%)	61.51k
SCYScandium International Mining Corp	$ 0.015 (-40.00%)	19k
DNDelta 9 Cannabis Inc	$ 0.01 (-33.33%)	2.01M
NCPNickel Creek Platinum Corp	$ 0.015 (-25.00%)	38.72k
SMCSulliden Mining Capital Inc	$ 0.015 (-25.00%)	612.1k
TRPTC Energy Corporation	$ 53.49 (0.19%)	20.76M
FCUFission Uranium Corp	$ 1.17 (-1.68%)	8.51M
CNQCanadian Natural Resources Ltd	$ 48.38 (-0.72%)	6.87M
MFCManulife Financial Corporation	$ 36.16 (1.03%)	6.49M
BTEBaytex Energy Corp	$ 4.68 (-0.21%)	4.87M